)
Visual
test
Spero Therapeutics
Spero Therapeutics (SPRO) investor relations material
Spero Therapeutics Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary26 Mar, 2026
Executive summary
Achieved significant progress in tebipenem HBr program for cUTI, including NDA resubmission and completion of global Phase 3 trial.
Licensing partner GSK announced FDA PDUFA date for tebipenem HBr as June 18, 2026.
Focused on fulfilling obligations under GSK license and exploring portfolio expansion opportunities.
Financial highlights
Net income for Q4 2025 was $31.5 million, compared to a net loss of $(20.9) million in Q4 2024.
Net income for full year 2025 was $8.6 million, versus a net loss of $(68.6) million in 2024.
Total revenue for Q4 2025 was $41.3 million, up from $15.0 million in Q4 2024, driven by increased collaboration revenue from GSK and Pfizer.
Full year 2025 revenue was $66.8 million, up from $48.0 million in 2024.
Cash and cash equivalents as of December 31, 2025, were $40.3 million.
Outlook and guidance
Cash and cash equivalents expected to fund operations into 2028.
Awaiting FDA decision on tebipenem HBr NDA by June 18, 2026.
Exploring opportunities to expand clinical-stage product portfolio.
Strategy for clinical-stage portfolio expansion
Impact of early trial termination on FDA labeling
Future milestone triggers from GSK and Pfizer
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Spero Therapeutics
- Q2 net loss was $17.9M as R&D spending rose; cash runway extends into late 2025.SPRO
Q2 20242 Feb 2026 - SPR720 nears pivotal data for NTM-PD, while Tebipenem HBr advances in phase III with GSK.SPROH.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026
- Advancing late-stage anti-infective therapies with major data and regulatory milestones ahead.SPRO2024 Cantor Fitzgerald Global Healthcare Conference20 Jan 2026
- Tebipenem HBr phase III interim analysis set for Q2 2025; cash runway into Q2 2026.SPROQ4 202424 Dec 2025
- Lead oral carbapenem asset nears phase III completion, with major milestones expected this year.SPROTD Cowen 45th Annual Healthcare Conference16 Dec 2025
- Stockholders to vote on director elections, auditor, executive pay, and stock plan amendment.SPROProxy Filing2 Dec 2025
- Annual meeting to vote on directors, auditor, executive pay, and stock plan share increase.SPROProxy Filing2 Dec 2025
- Tebipenem HBr Phase 3 trial met efficacy early, boosting revenue and extending cash runway into 2028.SPROQ2 202523 Nov 2025
- Tebipenem HBr met Phase 3 endpoint; FDA filing planned and financials improved.SPROQ3 202513 Nov 2025
Next Spero Therapeutics earnings date
Q1 202613 May, 2026
Spero Therapeutics
Next Spero Therapeutics earnings date
Q1 202613 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage